SEC filings and other documents

Innovative cancer therapies advance in clinic, supported by strong partnerships and financial discipline.

Advancing novel CAR-T and vaccine therapies for cancer with strong financial stability.

Net loss narrowed, cash remains strong, and clinical programs advance in cancer vaccines and CAR-T.

Net loss narrowed and liquidity remains strong as clinical programs advance in cancer therapies.

Advancing innovative cancer therapies with strong clinical data and a capital-efficient strategy.

Promising clinical progress and lean strategy set up key data catalysts in the next 12–18 months.

Innovative cancer therapies and vaccines advance with strong financials and key clinical milestones.

Board and executive actions approved; clinical programs advance with strong financial discipline.

Innovative cancer therapies and vaccines advance in clinic, supported by strong financials and partnerships.

Net loss narrowed, expenses declined, and clinical programs advanced with strong liquidity.

Pivotal data from advanced cancer trials and fiscal discipline set the stage for a transformative 2026.

Advancing first-in-class CAR-T and vaccine therapies for cancer with strong clinical progress.

Advancing first-in-class cancer therapies with strong early clinical results and major market potential.

Net loss narrowed to $11.0M as clinical programs advanced, with $15.2M in year-end liquidity.

Breast cancer vaccine phase I showed 75% robust immune response and strong safety profile.

Promising cancer therapies and vaccines show strong early results and major market potential.

Promising breast cancer vaccine data and disciplined financial strategy drive clinical progress.

Net loss narrowed on lower expenses; clinical trials progress, liquidity remains strong.

Phase one cancer vaccine and CAR-T programs show strong safety and early efficacy, with robust financials.

Promising cancer therapies advance with strong early data, efficient funding, and key milestones ahead.

Net loss narrowed and liquidity remains strong as Anixa advances cancer vaccine and CAR-T trials.

Promising phase I data and capital efficiency drive progress in breast and ovarian cancer programs.

Promising CAR-T and breast cancer vaccine data position the company for major 2025 milestones.

Q1 2025 net loss was $3.18M; strong liquidity supports ongoing cancer therapy R&D.